Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients (CAMELLIA–TIMI 61)

Sep 13, 2018

Overview : Trial References Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients - Thrombolysis in Myocardial Infarction 61 (CAMELLIA–TIMI 61) Expert Comment Amelia Carro. Hospital Universitario Vall d’Hebrón. Universidad Autónoma de Barcelona, Barcelona, Spain. Background Obesity is a major... more

Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE Trial)

Aug 27, 2018

Overview : Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE): A Randomised, Double-blind, Placebo-controlled Trial Trial Reference Gaziano JM, Brotons C, Coppolecchia R, et al. Use of Aspirin to Reduce Risk... more

A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest

Aug 27, 2018

Overview : Trial Reference Perkins GD, Ji C, Deakin CD, et al.; PARAMEDIC2 Collaborators. A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. N Engl J Med. 2018 Jul 18. doi: 10.1056/NEJMoa1806842. [Epub ahead of print] Abstract | Full Text Expert Comment Pablo Avanzas, Consultant... more

Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

May 22, 2018

Overview : Trial Reference Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, Ridker PM. Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes.  J Am Coll Cardiol. 2018 Mar 3. pii: S0735-1097(18)33483-1. doi: 10.1016/j.jacc.2018.03.002.... more

Effect of Loading Dose of Atorvastatin Prior to Planned PCI: The SECURE-PCI Randomized Clinical Trial

Apr 18, 2018

Overview : Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome. The SECURE-PCI Randomized Clinical Trial   Trial References Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin... more

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

Mar 22, 2018

Overview : Trial Reference White WB, Saag KG, Becker MA, et al; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 12. doi: 10.1056/NEJMoa1710895. [Epub ahead of print] Abstract | Full Text   Expert Comment... more

6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial

Mar 20, 2018

Overview : Trial Reference Hahn JY, Song YB, Oh JH, et al; SMART-DATE investigators. 6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial. Lancet. 2018 Mar 9.... more

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

Sep 06, 2017

Overview : Trial Reference Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017 Aug 27 [Epub ahead of print]. Abstract | Full Text   Expert Comment Pablo Avanzas,... more

ODYSSEY Long Term Study

Oct 15, 2014

Overview : The Odyssey Long Term Study evaluated the safety and efficacy of alirocumab (mAb anti-PCSK9) in 2341 patients with heterozygous FH or at high risk for cardiovascular events who were receiving a maximally tolerated dose of statin but who had an... more

: PARADIGM-HF. Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Oct 15, 2014

Overview : The the novel agent LCZ696 (Novartis) that has effects both within and beyond the renin-angiotensin system, was tested against of the ACE inhibitor enalapril, showing fewer HF hospitalizations and mortality from cardiovascular causes, acccording a phase 3 trial PARADIGM-HF. In... more

Page: